Sanofi’s (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder

The FDA approves Sanofi’s (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.